Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles by Dr. Adnan Kastrati
Based on 145 articles published since 2010
(Why 145 articles?)
||||

Between 2010 and 2020, A. Kastrati wrote the following 145 articles about Coronary Artery Disease.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6
1 Guideline 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. 2018

Valgimigli, Marco / Bueno, Héctor / Byrne, Robert A / Collet, Jean-Philippe / Costa, Francesco / Jeppsson, Anders / Jüni, Peter / Kastrati, Adnan / Kolh, Philippe / Mauri, Laura / Montalescot, Gilles / Neumann, Franz-Josef / Petricevic, Mate / Roffi, Marco / Steg, Philippe Gabriel / Windecker, Stephan / Zamorano, Jose Luis / Levine, Glenn N / Anonymous7100923. · ·Eur J Cardiothorac Surg · Pubmed #29045581.

ABSTRACT: -- No abstract --

2 Guideline Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. 2018

Byrne, Robert A / Stefanini, Giulio G / Capodanno, Davide / Onuma, Yoshinobu / Baumbach, Andreas / Escaned, Javier / Haude, Michael / James, Stefan / Joner, Michael / Jüni, Peter / Kastrati, Adnan / Oktay, Semih / Wijns, William / Serruys, Patrick W / Windecker, Stephan. ·Deutsches Herzzentrum München, Technische Universität München, Germany. ·EuroIntervention · Pubmed #28948934.

ABSTRACT: A previous Task Force of the European Society of Cardiology (ESC) and European Association of Percutaneous Cardiovascular Interventions (EAPCI) provided a report on recommendations for the non-clinical and clinical evaluation of coronary stents. Following dialogue with the European Commission, the Task Force was asked to prepare an additional report on the class of devices known as bioresorbable scaffolds (BRS). Five BRS have CE-mark approval for use in Europe. Only one device -the Absorb bioresorbable vascular scaffold- has published randomized clinical trial data and this data show inferior outcomes to conventional drug-eluting stents (DES) at 2-3 years. For this reason, at present BRS should not be preferred to conventional DES in clinical practice. The Task Force recommends that new BRS devices should undergo systematic non-clinical testing according to standardized criteria prior to evaluation in clinical studies. A clinical evaluation plan should include data from a medium sized, randomized trial against DES powered for a surrogate end point of clinical efficacy. Manufacturers of successful devices receive CE- mark approval for use and must have an approved plan for a large-scale randomized clinical trial with planned long-term follow-up.

3 Guideline 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). 2018

Valgimigli, Marco / Bueno, Héctor / Byrne, Robert A / Collet, Jean-Philippe / Costa, Francesco / Jeppsson, Anders / Jüni, Peter / Kastrati, Adnan / Kolh, Philippe / Mauri, Laura / Montalescot, Gilles / Neumann, Franz-Josef / Petricevic, Mate / Roffi, Marco / Steg, Philippe Gabriel / Windecker, Stephan / Zamorano, Jose Luis / Levine, Glenn N / Anonymous4980918 / Anonymous4990918 / Anonymous5000918. · ·Eur Heart J · Pubmed #28886622.

ABSTRACT: -- No abstract --

4 Guideline [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] 2017

Valgimigli, Marco / Bueno, Héctor / Byrne, Robert A / Collet, Jean-Philippe / Costa, Francesco / Jeppsson, Anders / Jüni, Peter / Kastrati, Adnan / Kolh, Philippe / Mauri, Laura / Montalescot, Gilles / Neumann, Franz-Josef / Peticevic, Mate / Roffi, Marco / Steg, Philippe Gabriel / Windecker, Stephan / Zamorano, Jose Luis. ·Cardiology, Inselspital, Bern. marco.valgimigli@insel.ch. ·Kardiol Pol · Pubmed #29251754.

ABSTRACT: -- No abstract --

5 Guideline 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). 2014

Kolh, Philippe / Windecker, Stephan / Alfonso, Fernando / Collet, Jean-Philippe / Cremer, Jochen / Falk, Volkmar / Filippatos, Gerasimos / Hamm, Christian / Head, Stuart J / Jüni, Peter / Kappetein, A Pieter / Kastrati, Adnan / Knuuti, Juhani / Landmesser, Ulf / Laufer, Günther / Neumann, Franz-Josef / Richter, Dimitrios J / Schauerte, Patrick / Sousa Uva, Miguel / Stefanini, Giulio G / Taggart, David Paul / Torracca, Lucia / Valgimigli, Marco / Wijns, William / Witkowski, Adam / Anonymous7870804 / Zamorano, Jose Luis / Achenbach, Stephan / Baumgartner, Helmut / Bax, Jeroen J / Bueno, Héctor / Dean, Veronica / Deaton, Christi / Erol, Çetin / Fagard, Robert / Ferrari, Roberto / Hasdai, David / Hoes, Arno W / Kirchhof, Paulus / Knuuti, Juhani / Kolh, Philippe / Lancellotti, Patrizio / Linhart, Ales / Nihoyannopoulos, Petros / Piepoli, Massimo F / Ponikowski, Piotr / Sirnes, Per Anton / Tamargo, Juan Luis / Tendera, Michal / Torbicki, Adam / Wijns, William / Windecker, Stephan / Anonymous7880804 / Sousa Uva, Miguel / Achenbach, Stephan / Pepper, John / Anyanwu, Anelechi / Badimon, Lina / Bauersachs, Johann / Baumbach, Andreas / Beygui, Farzin / Bonaros, Nikolaos / De Carlo, Marco / Deaton, Christi / Dobrev, Dobromir / Dunning, Joel / Eeckhout, Eric / Gielen, Stephan / Hasdai, David / Kirchhof, Paulus / Luckraz, Heyman / Mahrholdt, Heiko / Montalescot, Gilles / Paparella, Domenico / Rastan, Ardawan J / Sanmartin, Marcelo / Sergeant, Paul / Silber, Sigmund / Tamargo, Juan / ten Berg, Jurrien / Thiele, Holger / van Geuns, Robert-Jan / Wagner, Hans-Otto / Wassmann, Sven / Wendler, Olaf / Zamorano, Jose Luis / Anonymous7890804 / Anonymous7900804. ·(Belgium) philippe.kolh@chu.ulg.ac.be stephan.windecker@insel.ch. · (Switzerland) philippe.kolh@chu.ulg.ac.be stephan.windecker@insel.ch. · (Spain). · (France). · (Germany). · (Switzerland). · (Greece). · (Netherlands). · (Finland). · (Austria). · (Portugal). · (UK). · (Italy). · (Belgium). · (Poland). · (Turkey). · (Israel). · (Germany/UK). · (Czech Republic). · (Norway). · (USA). · (UK/Germany). ·Eur J Cardiothorac Surg · Pubmed #25173601.

ABSTRACT: -- No abstract --

6 Guideline 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). 2014

Anonymous7760804 / Windecker, Stephan / Kolh, Philippe / Alfonso, Fernando / Collet, Jean-Philippe / Cremer, Jochen / Falk, Volkmar / Filippatos, Gerasimos / Hamm, Christian / Head, Stuart J / Jüni, Peter / Kappetein, A Pieter / Kastrati, Adnan / Knuuti, Juhani / Landmesser, Ulf / Laufer, Günther / Neumann, Franz-Josef / Richter, Dimitrios J / Schauerte, Patrick / Sousa Uva, Miguel / Stefanini, Giulio G / Taggart, David Paul / Torracca, Lucia / Valgimigli, Marco / Wijns, William / Witkowski, Adam. · ·Eur Heart J · Pubmed #25173339.

ABSTRACT: -- No abstract --

7 Editorial Ten-Year Follow-Up of Left Main Coronary Artery Revascularization: Still Equipoise Between Percutaneous Interventions and Surgery? 2020

Alfonso, Fernando / Kastrati, Adnan. ·Department of Cardiology, Hospital Universitario de La Princesa, Madrid, Spain (F.A.). · Deutsches Herzzentrum München, Technische Universität, and the German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Germany (A.K.). ·Circulation · Pubmed #32223557.

ABSTRACT: -- No abstract --

8 Editorial Strengths and Limitations of Real World Data in Patients Treated With Coronary Stents. 2018

Byrne, Robert A / Colleran, Roisin / Kastrati, Adnan. ·Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (R.A.B., R.C., A.K.). · DZHK (German Centre for Cardiovascular Research), Munich Heart Alliance, Germany (R.A.B., A.K.). ·Circ Cardiovasc Interv · Pubmed #30354605.

ABSTRACT: -- No abstract --

9 Editorial Biodegradable-polymer drug-eluting stents: back to the future? 2017

Cassese, Salvatore / Xhepa, Erion / Kastrati, Adnan. ·Deutsches Herzzentrum München, Technische Universität München, Munich, Germany. · DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. ·Heart · Pubmed #27628493.

ABSTRACT: -- No abstract --

10 Editorial Bifurcation intervention with a two-stent strategy: can one size fit all? 2016

Colleran, Roisin / Byrne, Robert A / Kastrati, Adnan. ·Deutsches Herzzentrum München, Technische Universität München, Lazarettstrasse 36, 80636 Munich, Germany. · DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Biedersteiner Strasse 29, 80802 Munich, Germany. · Deutsches Herzzentrum München, Technische Universität München, Lazarettstrasse 36, 80636 Munich, Germany kastrati@dhm.mhn.de. ·Eur Heart J · Pubmed #27680609.

ABSTRACT: -- No abstract --

11 Editorial Bioresorbable Vascular Scaffold Technology Benefits From Healthy Skepticism. 2016

Cassese, Salvatore / Kastrati, Adnan. ·Deutsches Herzzentrum München, Technische Universität München, Munich, Germany. · Deutsches Herzzentrum München, Technische Universität München, Munich, Germany; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. Electronic address: kastrati@dhm.mhn.de. ·J Am Coll Cardiol · Pubmed #26916482.

ABSTRACT: -- No abstract --

12 Editorial Cardiogenic Shock: How Long Does the Storm Last? 2016

Kastrati, Adnan / Colleran, Roisin / Ndrepepa, Gjin. ·Deutsches Herzzentrum München, Technische Universität München, Munich, Germany; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. Electronic address: kastrati@dhm.mhn.de. · Deutsches Herzzentrum München, Technische Universität München, Munich, Germany. ·J Am Coll Cardiol · Pubmed #26892408.

ABSTRACT: -- No abstract --

13 Editorial Prognosis after revascularization for left main coronary artery disease: insights from the crystal ball. 2015

Byrne, Robert A / Kastrati, Adnan. ·Deutsches Herzzentrum München, Technische Universität München and DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany byrne@dhm.mhn.de. · Deutsches Herzzentrum München, Technische Universität München and DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. ·Eur Heart J · Pubmed #25784753.

ABSTRACT: -- No abstract --

14 Editorial Drug-eluting stents for drug-eluting stent restenosis: stick with the old or switch to a new one? 2014

Kufner, Sebastian / Kastrati, Adnan. ·aISA Research Center, Department of Cardiology, German Heart Center Munich bKlinikum rechts der Isar, Department of Cardiology, Technical University Munich cDZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. ·Coron Artery Dis · Pubmed #25365642.

ABSTRACT: -- No abstract --

15 Editorial A case where the principle of "one question, one answer" may work better. 2012

Tada, Tomohisa / Byrne, Robert A / Kastrati, Adnan. · ·Am Heart J · Pubmed #22305827.

ABSTRACT: -- No abstract --

16 Editorial Is diabetes the achilles' heel of limus-eluting stents? 2011

Kastrati, Adnan / Massberg, Steffen / Ndrepepa, Gjin. · ·Circulation · Pubmed #21859980.

ABSTRACT: -- No abstract --

17 Editorial More deserved focus on diabetic patients. 2011

Ndrepepa, Gjin / King, Lamin / Kastrati, Adnan. · ·Circ Cardiovasc Interv · Pubmed #21505164.

ABSTRACT: -- No abstract --

18 Editorial Is diabetes a leveler of efficacy of DES types? 2010

Kastrati, Adnan. · ·Catheter Cardiovasc Interv · Pubmed #20162698.

ABSTRACT: -- No abstract --

19 Review Percutaneous coronary intervention: balloons, stents and scaffolds. 2018

Colleran, Roisin / Kastrati, Adnan. ·Deutshes Herzzentrum München, Technische Universität München, Lazarettstr 36, 80636, Munich, Germany. · Deutshes Herzzentrum München, Technische Universität München, Lazarettstr 36, 80636, Munich, Germany. kastrati@dhm.mhn.de. · DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany. kastrati@dhm.mhn.de. ·Clin Res Cardiol · Pubmed #30039189.

ABSTRACT: In this review, major achievements in the field of percutaneous coronary interventions are delineated with particular focus on Germany's contribution. The review deals with important developments, including the first heart catheterization and coronary angiography, first coronary balloon angioplasty and refinement of the technique, coronary stenting and optimization of adjunctive antithrombotic treatment, drug-eluting stents and balloons, as well as bioresorbable polymeric and metallic drug-eluting scaffolds.

20 Review Incidence and predictors of reCurrent restenosis after drug-coated balloon Angioplasty for Restenosis of a drUg-eluting Stent: The ICARUS Cooperation. 2018

Cassese, Salvatore / Xu, Bo / Habara, Seiji / Rittger, Harald / Byrne, Robert A / Waliszewski, Matthias / Pérez-Vizcayno, María José / Gao, Runlin / Kastrati, Adnan / Alfonso, Fernando. ·Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universität München, München, Germany. Electronic address: cassese@dhm.mhn.de. · National Center for Cardiovascular Diseases, Fu Wai Hospital, Beijing, China. · Department of Cardiology, Kurashiki Central Hospital, Okayama, Japan. · Medizinische Klinik I, Klinikum Fürth, Fürth, Germany. · Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universität München, München, Germany. · Medical Scientific Affairs, B. Braun Vascular Systems, Berlin, Germany. · Fundación Interhospitalaria de Investigación Cardiovascular, Hospital Universitario Clínico San Carlos, Madrid, Spain. · Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universität München, München, Germany; German Centre for Cardiovascular Research (Deutsche Zentrum für Herz-Kreislauf-Forschung, DZHK), partner site Munich Heart Alliance, München, Germany. · Servicio de Cardiología, Hospital Universitario de La Princesa, Madrid, Spain. ·Rev Esp Cardiol (Engl Ed) · Pubmed #28916429.

ABSTRACT: INTRODUCTION AND OBJECTIVES: The incidence and predictors of recurrent restenosis after drug-coated balloon (DCB) angioplasty for drug-eluting stent (DES) restenosis remain poorly studied. We sought to evaluate the incidence and predictors of recurrent restenosis among participants in randomized controlled trials receiving DCB angioplasty for DES restenosis. METHODS: The clinical and lesion data of individuals enrolled in 6 randomized controlled trials of DCB angioplasty for DES restenosis were pooled. All patients included in this report were assigned to receive paclitaxel-coated balloon angioplasty with the SeQuent Please DCB (B Braun, Melsungen, Germany). The current analysis focused on participants with available follow-up angiography at 6 to 9 months. The incidence of recurrent restenosis, defined as diameter restenosis ≥ 50% in the in-segment area at follow-up angiography, and its clinical and angiographic predictors were evaluated. RESULTS: A total of 546 patients were combined in a single dataset. Angiographic follow-up at 6 to 9 months was available for 484 patients (88.6%) with 518 treated lesions. Recurrent restenosis was detected in 101 (20.8%) patients. On multivariable analysis, lesion length (OR, 1.58; 95%CI, 1.10-2.26; P=.012 for 5mm increase) and vessel size (OR, 1.42; 95%, 1.12-1.79; P=.003 for 0.5mm reduction) were independently associated with recurrent restenosis. CONCLUSIONS: In the largest cohort to date of individuals with angiographic surveillance after DCB angioplasty for DES restenosis, we demonstrated that recurrent restenosis occurs in approximately 1 out of 5 patients. Predictors of recurrent restenosis are increased lesion length and small vessel size.

21 Review Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients. 2017

D'Ascenzo, Fabrizio / Iannaccone, Mario / Saint-Hilary, Gaelle / Bertaina, Maurizio / Schulz-Schüpke, Stefanie / Wahn Lee, Cheol / Chieffo, Alaide / Helft, Gerard / Gili, Sebastiano / Barbero, Umberto / Biondi Zoccai, Giuseppe / Moretti, Claudio / Ugo, Fabrizio / D'Amico, Maurizio / Garbo, Roberto / Stone, Gregg / Rettegno, Sara / Omedè, Pierluigi / Conrotto, Federico / Templin, Christian / Colombo, Antonio / Park, Seung-Jung / Kastrati, Adnan / Hildick-Smith, David / Gasparini, Mauro / Gaita, Fiorenzo. ·Department of Cardiology, Città Della Salute e della Scienza Hospital, Corso Bramante 88/90, 10126 Turin, Italy. · Department of Cardiology, San Giovanni Bosco Hospital, Piazza del Donatore di Sangue 3, 10154 Turin, Italy. · Department of Mathematical Sciences "G. L. Lagrange", Politecnico di Torino, Corso Duca degli Abruzzi 24, 10129 Turin, Italy. · Department of Cardiology, Deutsches Herzzentrum München, Technische Universität München Lazarettstrasse 36, Munich 80636, Germany. · Department of Cardiology, The Heart Institute, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. · Interventional Cardiology Unit, San Raffaele Scientific Institute, Via Olgettina Milano, 60, 20132 Milan, Italy. · Department of Cardiology, Cardiology Institute, Pitié-Salpêtrière Hospital, UPMC, APHP, 47-83 Boulevard de l'Hôpital, 75013 Paris, France. · Department of Cardiology, University Heart Center, University Hospital Zurich, Rämistrasse 100, 8091 Zürich, Switzerland. · Department of Cardiology, La Sapienza, Piazzale Aldo Moro, 5, 00185 Rome, Italy. · Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Corso Della Repubblica 79, 04100 Latina, Italy. · Department of AngioCardioNeurology, IRCCS Neuromed, Via Atinense, 18, 86077 Pozzilli, Italy. · Department of Cardiology, Columbia University Medical Center, USA Cardiovascular Research Foundation, 161 Ft. Washington Ave. Herbert Irving Pavilion 6th Floor, New York, NY 10032 212.305.7060, USA. · Department of Cardiology, Sussex Cardiac Centre, Barry Building, Eastern Rd, Brighton BN2 5BE, UK. ·Eur Heart J · Pubmed #29020300.

ABSTRACT: Aims: The differential impact on ischaemic and bleeding events of the type of drug-eluting stent [durable polymer stents [DES] vs. biodegradable polymer stents vs. bioresorbable scaffolds (BRS)] and length of dual antiplatelet therapy (DAPT) remains to be defined. Methods and results: Randomized controlled trials comparing different types of DES and/or DAPT durations were selected. The primary endpoint was Major Adverse Cardiovascular Events (MACE) [a composite of death, myocardial infarction (MI), and target vessel revascularization]. Definite stent thrombosis (ST) and single components of MACE were secondary endpoints. The arms of interest were: BRS with 12 months of DAPT (12mDAPT), biodegradable polymer stent with 12mDAPT, durable polymer stent [everolimus-eluting (EES), zotarolimus-eluting (ZES)] with 12mDAPT, EES/ZES with <12 months of DAPT, and EES/ZES with >12 months of DAPT (DAPT > 12 m). Sixty-four studies with 150 arms and 102 735 patients were included. After a median follow-up of 20 months, MACE rates were similar in the different arms of interest. EES/ZES with DAPT > 12 m reported a lower incidence of MI than the other groups, while BRS showed a higher rate of ST when compared to EES/ZES, irrespective of DAPT length. A higher risk of major bleedings was observed for DAPT > 12 m as compared to shorter DAPT. Conclusion: Durable and biodegradable polymer stents along with BRS report a similar rate of MACE irrespective of DAPT length. Fewer MI are observed with EES/ZES with DAPT > 12 m, while a higher rate of ST is reported for BRS when compared to EES/ZES, independently from DAPT length. Stent type may partially affect the outcome together with DAPT length.

22 Review State of the art: coronary artery stents - past, present and future. 2017

Stefanini, Giulio G / Byrne, Robert A / Windecker, Stephan / Kastrati, Adnan. ·Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy. ·EuroIntervention · Pubmed #28844032.

ABSTRACT: The first percutaneous coronary intervention (PCI) was performed in September 1977 by Andreas Grüntzig using a rudimentary balloon angioplasty catheter mounted on a fixed wire. PCI was immediately recognised as a potential breakthrough in cardiovascular medicine, but uptake in clinical practice was limited by unpredictable acute outcomes and a need for surgical standby. The introduction of bare metal stents (BMS) in the 1980s improved procedure reproducibility and clinical outcomes through a permanent scaffolding of the coronary vessel, preventing abrupt occlusion and acute recoil. It was the introduction of drug-eluting stents (DES) at the beginning of this century, however, that allowed PCI to become one of the most frequently performed therapeutic interventions in medicine, primarily by addressing the issue of in-stent restenosis. DES technology has improved considerably since, with iterative developments of the stent metallic backbone, the polymer coating, and the released antiproliferative agents impacting on the safety and efficacy profile of these devices in a meaningful way. Overall, the impressive technological advances in metallic coronary stents have revolutionised the treatment of ischaemic heart disease over the last 40 years. The aim of the present article is to provide an overview of past, present, and future aspects of coronary stent technologies.

23 Review A laboratory association between hemoglobin and VerifyNow P2Y12 reaction unit: A systematic review and meta-analysis. 2017

Kim, Yun Gi / Suh, Jung-Won / Sibbing, Dirk / Kastrati, Adnan / Ko, Young-Guk / Jang, Yangsoo / Cho, Young-Seok / Youn, Tae-Jin / Chae, In-Ho / Choi, Dong-Ju / Kim, Hyo-Soo. ·Division of Cardiology, Department of Internal Medicine, Korea University Medical Center, Seoul, Republic of Korea. · Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Republic of Korea. Electronic address: dasome2@snu.ac.kr. · Ludwig-Maximilians-Universität München, München, Germany. · Deutsches Herzzentrum München, Technische Universität München, Munich, Germany. · Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. · Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Republic of Korea. · Cardiovascular Center, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. ·Am Heart J · Pubmed #28577681.

ABSTRACT: BACKGROUND: VerifyNow P2Y12 assay is used widely to evaluate residual platelet reactivity in patients taking P2Y12 receptor antagonists. However, a laboratory association between VerifyNow P2Y12 reaction unit (PRU) and hemoglobin, which might lead to wrong interpretation of the data, is reported. We performed these systematic review and meta-analysis to clearly define the relationship between PRU and hemoglobin and to elucidate whether the relationship, if any, is a true biological association or is just a laboratory error. METHODS: Through a comprehensive electronic and manual search, 10 studies were selected for the cohort level meta-analysis. Among 10 studies, we were able to retrieve the raw data of 5 studies, and a patient-level meta-analysis was performed. Potential publication bias was searched by funnel plot analysis and was actively adjusted, if present, by trim and fill method. RESULTS: The pooled analysis revealed a significant inverse correlation between PRU and hemoglobin (r=-0.349; P<.001; 10 studies with 4,793 patients). VerifyNow P2Y12 base unit, which reflects off-drug platelet reactivity, was also inversely correlated with hemoglobin (r=-0.526; P<.001; 8 studies with 4,395 patients). % Inhibition (r=0.081; P=.059; 6 studies with 3,832 patients) and ΔPRU (r=-0.037; P=.188; 5 studies with 3,521 patients) were not associated with hemoglobin. A significant inverse association between PRU and hemoglobin was also observed in the patient-level meta-analysis (3,533 patients pooled from 5 studies; r=-0.335; P<.001). Light transmission aggregometry (r=0.160; P=.072; 4 studies with 1,144 patients) and multiple electrode platelet aggregometry (r=-0.029; P=.394; 3 studies with 7,645 patients) showed no significant association with hemoglobin. CONCLUSIONS: A significant inverse association was observed between PRU and hemoglobin which is likely to be a laboratory error. Clinicians should be aware that this association might lead to wrong interpretation of the data.

24 Review Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. 2015

Byrne, Robert A / Joner, Michael / Kastrati, Adnan. ·Deutsches Herzzentrum München, Technische Universität München, Lazarettstr. 36, Munich, Germany. · Deutsches Herzzentrum München, Technische Universität München, Lazarettstr. 36, Munich, Germany DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany kastrati@dhm.mhn.de. ·Eur Heart J · Pubmed #26417060.

ABSTRACT: Modern-day stenting procedures leverage advances in pharmacotherapy and device innovation. Patients treated with contemporary antiplatelet agents, peri-procedural antithrombin therapy and new-generation drug-eluting stents (DES) have excellent outcomes over the short to medium term. Indeed, coupled with the reducing costs of these devices in most countries there remain very few indications where patients should be denied treatment with standard-of-care DES therapy. The two major causes of stent failure are stent thrombosis (ST) and in-stent restenosis (ISR). The incidence of both has reduced considerably in recent years. Current clinical registries and randomized trials with broad inclusion criteria show rates of ST at or <1% after 1 year and ∼0.2-0.4% per year thereafter; rates of clinical ISR are 5% respectively. Angiographic surveillance studies in large cohorts show rates of angiographic ISR of ∼10% with new-generation DES. The advent of high-resolution intracoronary imaging has shown that in many cases of late stent failure neoatherosclerotic change within the stented segment represents a final common pathway for both thrombotic and restenotic events. In future, a better understanding of the pathogenesis of this process may translate into improved late outcomes. Moreover, the predominance of non-stent-related disease as a cause of subsequent myocardial infarction during follow-up highlights the importance of lifestyle and pharmacological interventions targeted at modification of the underlying disease process. Finally, although recent developments focus on strategies which circumvent the need for chronically indwelling stents--such as drug-coated balloons or fully bioresorbable stents-more data are needed before the wider use of these therapies can be advocated.

25 Review Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. 2015

Byrne, Robert A / Serruys, Patrick W / Baumbach, Andreas / Escaned, Javier / Fajadet, Jean / James, Stefan / Joner, Michael / Oktay, Semih / Jüni, Peter / Kastrati, Adnan / Sianos, George / Stefanini, Giulio G / Wijns, William / Windecker, Stephan. ·Deutsches Herzzentrum München, Technische Universität München, Munich, Germany. · Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands. · Bristol Heart Institute, Bristol, UK. · Interventional Cardiology, Hospital San Carlos, Madrid, Spain. · Interventional Cardiology, Clinique Pasteur, Toulouse, France. · Clinical Research Center, Uppsala University, Uppsala, Sweden. · CVPath Institute, Inc., Gaithersburg, USA. · Cardio Med Device Consultants, Baltimore, USA. · Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland. · AHEPA University Hospital, Thessaloniki, Greece. · Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, Switzerland. · Cardiovascular Center O.L.V.Z., Aalst, Belgium. · Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, Switzerland stephan.windecker@insel.ch. ·Eur Heart J · Pubmed #26071600.

ABSTRACT: The evaluation for European Union market approval of coronary stents falls under the Medical Device Directive that was adopted in 1993. Specific requirements for the assessment of coronary stents are laid out in supplementary advisory documents. In response to a call by the European Commission to make recommendations for a revision of the advisory document on the evaluation of coronary stents (Appendix 1 of MEDDEV 2.7.1), the European Society of Cardiology (ESC) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) established a Task Force to develop an expert advisory report. As basis for its report, the ESC-EAPCI Task Force reviewed existing processes, established a comprehensive list of all coronary drug-eluting stents that have received a CE mark to date, and undertook a systematic review of the literature of all published randomized clinical trials evaluating clinical and angiographic outcomes of coronary artery stents between 2002 and 2013. Based on these data, the TF provided recommendations to inform a new regulatory process for coronary stents. The main recommendations of the task force include implementation of a standardized non-clinical assessment of stents and a novel clinical evaluation pathway for market approval. The two-stage clinical evaluation plan includes recommendation for an initial pre-market trial with objective performance criteria (OPC) benchmarking using invasive imaging follow-up leading to conditional CE-mark approval and a subsequent mandatory, large-scale randomized trial with clinical endpoint evaluation leading to unconditional CE-mark. The data analysis from the systematic review of the Task Force may provide a basis for determination of OPC for use in future studies. This paper represents an executive summary of the Task Force's report.

Next